Lumenda

Facebook
Twitter
LinkedIn

In developing countries, the cost to diagnose meningitis remains high and therefore many neonates are denied quality healthcare. Approximately 126,000 cases of neonatal bacterial meningitis occur every year in low income countries of which 25–50% develop brain damage and about 40-58% of patients die. The gold standard for diagnosing neonatal bacterial meningitis is a cerebrospinal fluid (CSF) culture. Lumenda provides an accurate and rapid method of diagnosing bacterial meningitis in neonates in low-resource settings. It facilitates rapid intervention and avoids wasteful prophylactic administration of antibiotics by analyzing the optical properties of the CSF to rapidly detect bacterial meningitis at each point along this pathophysiology. The rationale behind the device stems from the clinical observation that CSF turns from clear to opaque when infected with bacterial meningitis.

More Winners

MÄk (UC Berkeley)

MÄk is a social enterprise devoted to empowering urban low-income high school juniors and seniors to become 3D designers. The mission of MÄk is to

Read More »

CA$HFLOW

CA$HFLOW from Big Ideas @ Berkeley on Vimeo. To combat increasing student debt from rising tuition fees by bringing financial literacy to high schools. CA$HFLOW’s

Read More »

LuxWalk (UC Berkeley)

The three main functions of the LuxWalk application are as follows. First, students can input their origin and destination on an app built into the

Read More »

© 2021 Blum Center for Developing Economies

Design by Joseph Kim